Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


How Middle Eastern Markets Are Transforming Drug Reviews And Driving Competitiveness

Executive Summary

The UAE, Jordan, Egypt and Saudi Arabia have all recently announced or implemented new verification/abridged regulatory pathways to improve access to medicines and free up resources.

You may also be interested in...

Middle East And North Africa Dip Toes In HTA And Access Agreements

Saudi Arabia is set to introduce a new pricing policy that will affect the rest of the region.

Amryt On Targeting Rare Disease Space In The Middle East

The rare and orphan drug company Amryt speaks to the Pink Sheet about how to do business in the Middle East and why seeking marketing authorization could be a better long-term strategy than catering for named patient requests.

Kuwait’s New Fast-Track Approval System Follows Regional Trend

Kuwait is the latest market in the Middle East to introduce a new regulatory procedure for speeding up market entry of innovative new drugs. However, industry experts would like to see it go further.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts